Hansen, Anne S.
Nielsen, René E.
Christensen, Jakob
Stone, Jon
Rask, Charlotte U.
Article History
Received: 13 July 2020
Accepted: 17 July 2020
First Online: 28 July 2020
Competing interests
: J.C. has received honoraria for serving on the Scientific Advisory Board of Union Chimique Belge (UCB) Nordic and Eisai AB and for giving lectures for UCB Nordic and Eisai, as well as travel funds from UCB Nordic and funding by the Novo Nordisk Foundation (grant number: NNF16OC0019126), the Central Denmark Region and the Danish Epilepsy Association. R.E.N. has received research grants from H. Lundbeck, Compass Pharmaceuticals, Janssen-Cilag, Boehringer and Otsuka Pharmaceuticals for clinical trials, has received speaking fees from Bristol-Myers Squibb, Astra Zeneca, Janssen & Cilag, H. Lundbeck, Servier, Otsuka Pharmaceuticals, Teva and Eli Lilly, and has acted as advisor to Astra Zeneca, Eli Lilly, Lundbeck, Otsuka Pharmaceuticals, Takeda and Medivir. J.S. receives honoraria from UpToDate and carries out expert witness work in relation to functional neurological disorders. The remaining authors have no financial relationships relevant to this article to disclose.